Investorideas.com
Search  Follow Investorideas on Twitter  Investorideas is on Facebook  Investorideas is on Google Plus  Investorideas is on Youtube  Investorideas is on Pinterest  Investorideas is on tumblr  Investorideas is on LinkedIn  Investorideas RSS 


Investorideas podcasts on iTunes, Google Play Music and iHeart.com    Investorideas.com potcasts - cannabis news and stocks to watch plus insight from thought leaders and experts    Investorideas.com crypto corner    Play by Play – the latest sports headlines and sports stock news

 

Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories

Syneos Health (Nasdaq: $SYNH): When It Comes to Artificial Intelligence in Healthcare, Patients Fear the Replacement of Doctors, Yet Are Open to AI Nurse Support

New Data from Global Survey Reveals Expectations and Concerns of Patients and Caregivers Confronting a Future with Artificial Intelligence

 

RALEIGH, N.C. - February 6, 2018 (Investorideas.com Newswire) Syneos Health Communications today released a report that provides pioneering perspectives into patients' thought processes as they confront a future with artificial intelligence (AI). The first of its kind research reveals that excitement over healthcare AI in the scientific and investor communities doesn't necessarily translate into enthusiasm from patients and caregivers at the receiving end of AI services.

While more than 300 venture capital and private equity deals have funded healthcare AI experiments over the last five years, the conversation has been primarily led by technologists, scientists, or providers focused on the potential role of AI in predicting or diagnosing conditions. Until now, the missing component in this AI healthcare conversation has been patient and caregiver perspectives.

This report provides that missing link with survey research compiled across approximately 800 European and American patients in three disease areas - atrial fibrillation, Type 2 diabetes, breast cancer - and 200 caregivers for people with Parkinson's disease.i

Findings include:

Fears of AI in Healthcare: The survey indicates that the top two fears patients and caregivers have when it comes to artificial intelligence are lack of human oversight and the potential for machine errors leading to mismanagement of their health.

No Substitute for Your Doctor: When it comes to the possibilities of doctors being replaced by algorithms or robots, fears are clearly evident with fewer than 20 percent of patients surveyed perceiving any benefit to their future healthcare in receiving diagnosis or treatment recommendations from a virtual assistant.

Strong Comfort in Using AI to Scale and Support Nurses: Switch the focus to the critical role played by nurses in supporting patients, and a different picture emerges.

  • Three times as many respondents (64 percent) would be comfortable with artificially intelligent virtual nurse assistants. The number one benefit is seen as 24x7 on-demand access to answers and support, followed by monitoring for their general health and wellness, or for questions around a specific medication they've been prescribed.
  • Patients also have strong views on how "human" any virtual nurse assistants need to be. A ‘realistic voice' with a professional, warm and empathetic tone is seen as appealing by 72 percent - more important than a human name, face or gender.

Appropriate Providers of AI: When asked to rank potential providers of AI-powered virtual nurse assistants in terms of trust, tech companies are toward the bottom of the list, alongside insurers. Healthcare providers such as doctors, pharmacists or hospitals rank highest.

"Syneos Health Communications believes that technology giants viewing healthcare as their next big opportunity must address patient and caregiver concerns about trust, control and oversight," said Michelle Keefe, President, Syneos Health Commercial Solutions. "A structured and deliberate multi-channel marketing and communications approach will be essential to generate the desired efficiencies and behavioral outcomes AI can achieve."

Syneos Health explored these issues with panelists from Verily, Verantos, Celgene, Prognos and Evidation Health at a panel on artificial intelligence in healthcare at the Digital Medicine & Medtech Showcase hosted in San Francisco in January. The report further explores how AI can play a role in adherence, clinical trials, at the pharmacy and includes implications for life science brands.

The report - "Artificial Intelligence for Authentic Engagement: Patient Perspectives on Healthcare's Evolving AI Conversation" - is available for free download at syneoshealthcommunications.com. In addition to the survey results, it also contains insights from follow-up focus groups exploring current ideas, expectations and concerns from these patients and caregivers. http://syneoshealthcommunications.com/perspectives/artificial-intelligence-for-authentic-engagement

About Syneos Health Communications

Syneos Health Communications is the only healthcare communications network that is part of a company on the frontlines of healthcare, with a clear view into the everyday complexities of life and health. As part of Syneos HealthTM, our agencies - consisting of leading brands and experts in advertising, branding, public relations, managed markets and medical communications - are engaged in every point of influence in health, providing real-world insight into markets and audiences in ways that no other partner could.

We work in scalable, collaborative teams that partner across disciplines and geographies to deliver integrated communications strategies that accelerate brand performance. Our agency teams have received more than 1,000 awards for work that disrupts markets and drives behavior change. We create ideas that will work in the real world because they were built there.

Find out more at syneoshealthcommunications.com.

About Syneos Health

Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies - INC Research and inVentiv Health - we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers' delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to lifeTM visit syneoshealth.com.

Cautionary Statement Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: risks associated with the integration of our business with the business of inVentiv Health, and our operation of the combined business following the closing of the Merger; our ability to maintain or generate new business awards; our ability to increase our market share, grow our business, and execute our growth strategies; our backlog not being indicative of future revenues and our ability to realize the anticipated future revenue reflected in our backlog; our ability to adequately price our contracts and not overrun cost estimates; general and international economic, political, and other risks, including currency and stock market fluctuations and the uncertain economic environment; fluctuations in our financial results; reliance on key personnel; our customer or therapeutic area concentration; and the other risk factors set forth in our Form-Q for the quarter ended September 30, 2017, and other SEC filings, copies of which are available free of charge on our website at investor.syneoshealth.com. Syneos Health assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Contacts

Investor Relations:

Ronnie Speight
Vice President, Investor Relations
+1 919 745 2745
Investor.Relations@syneoshealth.com

Press/Media:

Danielle DeForge
Senior Director, External Communications
+1 202 210 5992
danielle.deforge@syneoshealth.com


TechSectorStocks.com - investing ideas in tech stocks- mobile payments, social media, AI and Robotics, Drone Stocks, GPS, Internet of Things (IoT)

Like Tech Stocks? View our Tech Stocks Directory



More Info:

Investorideas.com Newswire

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire http://www.investorideas.com/News-Upload/

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: http://www.investorideas.com/About/Private_Policy.asp